Share

Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?

A conversation with Nobel Laureate Paul Nurse, president, the Rockefeller University

Dr. Nurse, 2001 Nobel Prize winner in Medicine, will appear at Sixth & I for a critical examination of the latest breakthroughs in the biological sciences and their potential to transform medical treatment. Dr. Nurse spent over three decades as a research scientist in the United Kingdom, where he was born. His research led to the identification of cyclin-dependent kinase (CDK) as the key regulator molecule controlling the process by which cells make copies of themselves. This is important for understanding growth, development and cancer. His most recent post was as head of the world's largest volunteer-supported cancer research organization, Cancer Research UK.

Laura Landro, editor and award winning writer for The Wall Street Journal will interview Dr. Nurse about biomedical research in general, cancer research in particular, and his passionate commitment to promoting fruitful dialogue between scientists and society.

In 1991, Laura Landro was diagnosed with a form of blood cancer called chronic myelogenous leukemia. Over the course of the months and years that followed, she used her training as a reporter to obtain critical information about the disease affecting her, improving her ability to interact with her doctors and eventually emerging as a survivor. Laura won the National Print Journalism Award from the Leukemia Society of America for her WSJ article, "A Survivor's Tale," and is the author of Survivor: Taking Control of Your Fight Against Cancer; she remains an outspoken advocate of patient empowerment through education.

Sixth & I Historic Synagogue is a magnificent newly restored historic synagogue that is now a cutting-edge cultural center. Sixth & I is a non-denominational, non-membership, non-traditional synagogue in the heart of downtown Washington. We are committed to providing world-class programming and a variety of exceptional services to its target audience of young and unaffiliated Jews, particularly in the 20-35 age groups, as well as to the general community at large.

Share

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.